£15m of financial backing secured for Biotech start- up SolasCure

Science

The Cambridge based company and Biotech start-up, SolasCure, has broadcast the conclusion of its £15 million series A financing from industry veterans, institutional venture and strategic investors to fund their wound cleaning product, Aurase®.

SolasCure is in the process of creating exclusive technology leveraging biomimicry and evidence-based medicine to authorize healthcare specialists to help patients with long-lasting injuries. Aurase, their first product, is a hydrogel comprising of an enzyme cloned from medical maggots.

“SolasCure is in the process of creating exclusive technology leveraging biomimicry and evidence-based medicine to authorize healthcare specialists to help patients with long-lasting injuries“

Dr Sam Bakri, SolasCure’s Founder and CEO said “We are delighted to have completed our Series A round, which will help us to move onto the clinical trial stages of product development. We are excited to be working with such knowledgeable and specialist investors, as they join us on our mission to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.”

CEO of BRAIN Biotech AG, Adriaan Moelker, expressed “It has been an encouraging sign for all partners that SolasCure has been able to successfully close another financing round with rising pre-money valuation during the pandemic. We continue to be committed to support SolasCure on its way to market for the innovative wound debridement enzyme Aurase. “

Speaking about the Seneca Partners investment, Investment Director Matt Currie said “We are delighted to support SolasCure as part of this latest funding round. The team they have brought together are truly world-class, producing ground-breaking work in the wound care sector. Practitioners are crying out for a high-quality solution that can be transported, stored, and administered in an efficient and effective way – something severely lacking in the treatments available at present. We believe SolasCure’s Aurase product has the potential to become the go-to solution in this space.”

See all the latest jobs in Science
Return to news